ライフサイエンスコーパス: liver transplantation

1 is at the forefront of innovation in modern liver transplantation.

2 , dose-escalation, Phase I clinical trial in liver transplantation.

3 orse prognosis for recipient and graft after liver transplantation.

4 e to disease progression and 26 proceeded to liver transplantation.

5 adverse health outcomes following pediatric liver transplantation.

6 in an in situ and ex situ model of rat donor liver transplantation.

7 DO donors are underutilized in pediatric liver transplantation.

8 tion of organoids for tissue engineering and liver transplantation.

9 C locus are less likely to suffer TCMR after liver transplantation.

10 tial therapy for PTLD arising after renal or liver transplantation.

11 6 genotypes on liver graft fat content after liver transplantation.

12 machine perfusion (NMP) and after orthotopic liver transplantation.

13 would benefit from earlier consideration of liver transplantation.

14 henomenon also occurs following living donor liver transplantation.

15 llowed by simultaneous donor bone marrow and liver transplantation.

16 ciated with a reduced incidence of AKI after liver transplantation.

17 achieve optimal outcomes in uDCD kidney and liver transplantation.

18 agnosis of liver disease or having undergone liver transplantation.

19 ely ill men with cirrhosis undergoing urgent liver transplantation.

20 s recently become the leading indication for liver transplantation.

21 E in reducing the incidence of NAS after DCD liver transplantation.

22 enal safety of MRI with gadolinium following liver transplantation.

23 those patients most likely to die or require liver transplantation.

24 One patient (0.005%) underwent liver transplantation.

25 ELS is rarely used in the setting of liver transplantation.

26 ntly reported in children who have undergone liver transplantation.

27 ry cholangitis (PBC) frequently recurs after liver transplantation.

28 tation Society consensus meeting on NAFLD in liver transplantation.

29 ies are necessary to facilitate a successful liver transplantation.

30 f the screened population actually underwent liver transplantation.

31 with hereditary transthyretin amyloidosis is liver transplantation.

32 osure and immune-mediated graft injury after liver transplantation.

33 bly made its way into decision making within liver transplantation.

34 ve therapies, such as surgical resection and liver transplantation.

35 es include surgical resection, ablation, and liver transplantation.

36 Most (93%) had undergone renal or liver transplantation.

37 scontinuation of immunosuppression following liver transplantation.

38 er disease and assessing liver health before liver transplantation.

39 rence to immunosuppressive medications after liver transplantation.

40 in chronic ductular scarring, necessitating liver transplantation.

41 s to limit the lives of patients who require liver transplantation.

42 MGB1 oxidation states in human IRI following liver transplantation.

43 had the strongest association in kidney and liver transplantation.

44 and is the second most common indication for liver transplantation.

45 for the use of organs from elderly donors in liver transplantation.

46 he benchmark values observed in standard DBD liver transplantation.

47 plantation but there is no clear evidence in liver transplantation.

48 clinical outcomes, particularly surrounding liver transplantation.

49 survival comparable to other indications for liver transplantation.

50 NSBB in patients with cirrhosis referred for liver transplantation.

51 ients, including HCC (8/49), death (8/49) or liver transplantation (2/49).

52 Patients on the waitlist for liver transplantation 2007-2016 were identified in Scien

53 1.46 life years for patients offered delayed liver transplantation (4.49-fold increase).

54 , history of hepatocellular carcinoma and/or liver transplantation (7.74 [3.82-15.69], P < 10(-3) ),

55 ng data from the adult-to-adult living donor liver transplantation (A2ALL) study, which represents th

56 substantial reduction in organ donation and liver transplantation activity across the 3 countries wi

57 nited Kingdom and resumption of living donor liver transplantation activity in India toward the end o

58 Liver transplantation after cDCD is associated with high

59 improvements in long-term survival following liver transplantation among 1-year survivors.

60 hs of follow-up 11 patients (9.7%) underwent liver transplantation and 17 (15.1%) died (13 deaths wer

61 sible in most cases, 11 of 70 (16%) required liver transplantation and 8 (11%) died.

62 -LLS requires expertise in both living donor liver transplantation and advanced laparoscopic liver su

63 Racial disparities have been reported in liver transplantation and chronic hepatitis C treatment

64 crobiome in determining graft function after liver transplantation and demonstrate the benefits of an

65 rejection (subTCMR) is commonly found after liver transplantation and has a good short-term prognosi

66 men, malignancies, and advances in pediatric liver transplantation and liver transplant anesthesia.

67 sely monitor these patients lifelong despite liver transplantation and maintain multidisciplinary wor

68 e components of metabolic syndrome following liver transplantation and provide practical stepwise gui

69 Liver transplantation and PSC-related events accounted f

70 ifferent for deceased donor and living donor liver transplantation and varied between centers within

71 Liver transplantation appeared to have a beneficial effe

72 and biochemical markers of cholestasis after liver transplantation are associated with PBC recurrence

73 e competing risk regressions (deceased donor liver transplantation as the competing risk) to detect d

74 and competing risk regression analyses (with liver transplantation as the competing risk) to estimate

75 tosis in a liver graft is mandatory prior to liver transplantation, as the risk of graft failure incr

76 ofiles that correlated with survival without liver transplantation at 24 months of age.

77 1,118 patients who underwent evaluation for liver transplantation at the six Veterans Affairs' trans

78 A patient on waitlist for orthotopic liver transplantation because of decompensated liver cir

79 y chronic Cryptosporidium infection required liver transplantation before HSCT.

80 blation therapy for presumed HCC followed by liver transplantation between January 2011 and December

81 rrhosis, who were referred and evaluated for liver transplantation between January and June 2012 were

82 is not a standard procedure for living donor liver transplantation but is safe and reproducible in th

83 e sole criterion for delisting a patient for liver transplantation, but rather should be considered o

84 tases of a digestive origin underwent hybrid liver transplantation by pure laparoscopic total hepatec

85 However, liver transplantation can be challenging and should be r

86 ive treatment for biliary tract cancers, and liver transplantation can be curative in selected patien

87 report by Galante A and colleagues regarding liver transplantation carried out in a patient with deng

88 ly associated with survival for 1 year after liver transplantation CONCLUSIONS: In an analysis of dat

89 Increasing split liver transplantation could increase organ availability

90 n 20 Gy (dose-dependent, both p<0.0001); for liver transplantation, dactinomycin (3.8, 1.3-11.3) and

91 acted geographic disparity in deceased donor liver transplantation (DDLT) across donation service are

92 ransplantation, its impact in deceased donor liver transplantation (DDLT) is unclear.

93 of ex situ machine preservation in clinical liver transplantation, describing the most important tec

94 tageous to protect from HCC recurrence after liver transplantation, despite extended tumor criteria.

95 echnical aspects of living donor (LD) domino liver transplantation (DLT) in maple syrup urine disease

96 Most patients are not candidates for liver transplantation even if they have end-stage liver

97 , HCV variants escaping nAb responses during liver transplantation exhibited a significantly higher r

98 Early liver transplantation for alcoholic hepatitis is a poten

99 datory to properly evaluate the candidate to liver transplantation for alcoholic liver diseases and s

100 precludes curative oncological resection or liver transplantation for cholangiocarcinoma (CCA).

101 dy was to investigate tumor recurrence after liver transplantation for hepatocellular carcinoma (HCC)

102 Six patients underwent liver transplantation for hepatocellular carcinoma or ad

103 A cohort of 43 children who had undergone liver transplantation for nonautoimmune liver disease at

104 Liver transplantation for patients with acute-on-chronic

105 deled long-term outcomes of early vs delayed liver transplantation for patients with AH.

106 tand are associated with increased access to liver transplantation for patients with low EA.

107 These findings support early liver transplantation for patients with severe AH.

108 rogress to end-stage liver disease requiring liver transplantation for survival.

109 care costs, including impact on the need for liver transplantation, for which nonalcoholic steatohepa

110 001), which strongly associated with reduced liver transplantation-free survival (log-rank P < .001).

111 successfully vaccinated infant who underwent liver transplantation from an donor positive for antibod

112 Short of liver transplantation, goal-directed haemodynamically ta

113 Liver transplantation has been increasingly reported ove

114 Liver transplantation has been shown to be a therapeutic

115 Complexity of combined heart-liver transplantation has resulted in low adoption rates

116 Gains in short-term survival following liver transplantation have been gratifying.

117 Although short-term outcomes for liver transplantation have improved, patient and graft s

118 Mechanical ventilation at liver transplantation (hazard ratio [HR] 1.49; 95% confi

119 t of NASH and the clinical practice in fatty liver transplantation, highlights its limitations and op

120 es of adult patients receiving en-bloc heart-liver transplantation (HLTx), describe technical aspects

121 There is a limited access to liver transplantation, however, many organs are discarde

122 In the field of liver transplantation, however, no studies exist on reli

123 sease that is the leading cause of pediatric liver transplantation, however, the mechanism of disease

124 the upper limit of normal) at 6 months after liver transplantation (HR, 1.79; 95% CI, 1.16-2.76; P =

125 e cohort study assessing outcomes after cDCD liver transplantation in 1 Swiss (HOPE) and 6 French (NR

126 iewed all published court opinions involving liver transplantation in 2 legal databases (Lexis Nexus

127 series that described the use of ECMO after liver transplantation in adult recipients.

128 ignificant contraction in organ donation and liver transplantation in all 3 countries.

129 like in adults is a very rare indication for liver transplantation in children.

130 death (DCD) allografts on outcomes following liver transplantation in fulminant hepatic failure (FHF)

131 f acute liver failure, resulting in death or liver transplantation in more than one third of patients

132 ute alcoholic hepatitis are not eligible for liver transplantation in most transplant centers.

133 th reduced odds of survival for 1 year after liver transplantation in patients with ACLF-3.

134 is the main cause of acute liver failure and liver transplantation in several Western countries.

135 ojected to become the leading indication for liver transplantation in the next decade.

136 NAFLD cirrhosis is a leading indication for liver transplantation in the United States.

137 rhosis due to NASH the second indication for liver transplantation in the United States.

138 heart transplantation versus combined heart-liver transplantation in these patients, a multidiscipli

139 This removes one of the last barriers to liver transplantation in this challenging cohort of reci

140 ver transplants and the utilization of split liver transplantation in this donor population.

141 cause of acute liver failure (ALF) requiring liver transplantation in USA and its frequency is increa

142 Compared with delayed transplantation, early liver transplantation increased survival times in all si

143 In hepatology/liver transplantation, investigation of frailty has larg

144 Getting listed for liver transplantation is a complex process.

145 Salvage liver transplantation is an efficient treatment of recur

146 Acute kidney injury (AKI) after liver transplantation is associated with increased morbi

147 The only therapy apart from liver transplantation is augmentation with human AAT pro

148 ombosis (PVTT) is 2-6 months; conventionally liver transplantation is contraindicated.

149 Liver transplantation is essential for survival of patie

150 Evaluation for liver transplantation is indicated when spontaneous reso

151 Overall, the 1-year survival rate following liver transplantation is lower than that seen in patient

152 Pediatric liver transplantation is often required as a consequence

153 Liver transplantation is one of the treatments for patie

154 owever, there is increasing evidence that if liver transplantation is performed in selected patients

155 disease in children; however, unlike adults liver transplantation is rarely required as treatment.

156 The principle in right lobe living donor liver transplantation is to use "near-perfect" grafts to

157 n determining graft outcomes in living donor liver transplantation, its impact in deceased donor live

158 Kidney after liver transplantation (KALT) is the best therapeutic opt

159 underwent total hepatectomy and living donor liver transplantation (LDLT) by left lateral segment gra

160 Living donor liver transplantation (LDLT) enjoys widespread use in As

161 nd Europe; however, the data on living donor liver transplantation (LDLT) for ALD remain sparse.

162 The main concern with live donor liver transplantation (LDLT) is the risk to the donor.

163 We studied outcomes following living donor liver transplantation (LDLT) post-PVTT downstaging (DS)

164 , 1.79; 95% CI, 1.36-2.36; P < .001), age at liver transplantation <60 years (HR, 1.39; 95% CI, 1.02-

165 The role of liver transplantation (LT) and exception point waitlist

166 n early calcineurin inhibitors exposure post-liver transplantation (LT) and long-term outcomes.

167 ous recovery (NSR): Seven patients underwent liver transplantation (LT) and one patient died before L

168 c factors of primary graft dysfunction after liver transplantation (LT) are available, it remains dif

169 ave described vasomodulator (VM) therapy and liver transplantation (LT) as treatment options.

170 Patients with ACLF-3 who underwent liver transplantation (LT) between 2007 and 2017 in 5 tr

171 Liver transplantation (LT) centers should adapt to the p

172 cation, era, and time period ("epoch") after liver transplantation (LT) could have implications for s

173 For those requiring liver transplantation (LT) during adolescence, disparity

174 atocellular carcinoma (HCC) recurrence after liver transplantation (LT) exist.

175 In some states, liver transplantation (LT) for alcohol-associated liver

176 nce of donor-specific antibodies (DSA) after liver transplantation (LT) for graft and patient surviva

177 apy has altered the frequency and outcome of liver transplantation (LT) for hepatitis C virus (HCV).

178 The effect of height and sex on liver transplantation (LT) for hepatocellular carcinoma

179 ng/mL is associated with poor outcomes after liver transplantation (LT) for hepatocellular carcinoma

180 benefit of sirolimus in patients undergoing liver transplantation (LT) for hepatocellular carcinoma

181 tases (i-CRLM) BACKGROUND:: A renaissance of liver transplantation (LT) for i-CRLM has been recently

182 Liver transplantation (LT) for polycystic liver disease

183 The national landscape of liver transplantation (LT) for unauthorized immigrants i

184 Liver transplantation (LT) from controlled donation afte

185 usoidal endothelial cell (SEC) injury during liver transplantation (LT) has been previously addressed

186 giocarcinoma (iCCA) is a contraindication to liver transplantation (LT) in most centers worldwide.

187 ational policy granting priority listing for liver transplantation (LT) in patients who achieved down

188 er differences in evaluation and listing for liver transplantation (LT) in patients with ALD.

189 is no consensus to determine suitability for liver transplantation (LT) in the elderly.

190 CC) is an increasingly common indication for liver transplantation (LT) in the United States and in m

191 e is limited data on HHT patients undergoing liver transplantation (LT) in the United States.

192 rhosis is the fastest growing indication for liver transplantation (LT) in the United States.

193 Liver transplantation (LT) in young patients is being pe

194 m use of calcineurin inhibitors (CNIs) after liver transplantation (LT) is associated with nephrotoxi

195 y sclerosing cholangitis (PSC), pre and post-liver transplantation (LT) is unclear.

196 In the United Kingdom, liver transplantation (LT) is undertaken in 7 supraregio

197 Arterial conduits (AC) in liver transplantation (LT) offer an effective rescue opt

198 ith cirrhosis and portal hypertension, prior liver transplantation (LT) or severe extra-hepatic manif

199 her liver diseases, but the effect of age on liver transplantation (LT) outcomes in this population a

200 reating uncertainty toward the management of liver transplantation (LT) programs.

201 Time spent on the waiting list before liver transplantation (LT) provides an opportunity to op

202 nism to combat the geographic disparities in liver transplantation (LT) rates.

203 e prevalence and patterns of liver injury in liver transplantation (LT) recipients with COVID-19 are

204 We evaluated trends and outcomes of liver transplantation (LT) recipients with/without HIV i

205 e impact of pre-existing and new-onset DM on liver transplantation (LT) recipients.

206 predict recovery of renal function following liver transplantation (LT) remains elusive.

207 dysbiosis and its rate of recovery following liver transplantation (LT) remains incompletely understo

208 long-term cardiovascular events (CVE) after liver transplantation (LT) remains scarce.

209 m glycomic signature in the first week after liver transplantation (LT) that is associated with graft

210 e is a paucity of data on the outcome of DCD liver transplantation (LT) utilizing livers with macrost

211 during immunosuppression (IS) withdrawal in liver transplantation (LT) was associated with acute rej

212 patocellular carcinoma (HCC) recurring after liver transplantation (LT) when HCC is unsuitable for su

213 n effective technique for arterialization in liver transplantation (LT) when the native recipient art

214 Among 3060 patients undergoing liver transplantation (LT), 45 (1.5%) underwent ReLT-KT.

215 ity in patients with cirrhosis evaluated for liver transplantation (LT), longer hospital and intensiv

216 ecome one of the most common indications for liver transplantation (LT), particularly in candidates o

217 ical outcomes of POPH patients who underwent liver transplantation (LT).

218 optimization of donor-recipient matching in liver transplantation (LT).

219 wnstaging liver-directed therapy to curative liver transplantation (LT).

220 lity in patients with cirrhosis referred for liver transplantation (LT).

221 nction scarcely studied in patients awaiting liver transplantation (LT).

222 ved to contribute to graft dysfunction after liver transplantation (LT).

223 cellular carcinoma (HCC) patients undergoing liver transplantation (LT).

224 a common and debilitating side effect after liver transplantation (LT).

225 could result into worse renal outcomes after liver transplantation (LT).

226 last computed tomography (CT) imaging before liver transplantation (LT).

227 in a variety of clinical settings including liver transplantation (LT).

228 nd hepatocellular carcinoma (HCC) listed for liver transplantation (LT).

229 rtant cause of morbidity and mortality after liver transplantation (LT).

230 r of EAD and a predictor of graft loss after liver transplantation (LT).

231 unistic pathogens that cause morbidity after liver transplantation (LT).

232 fy 90-day mortality of patients referred for liver transplantation (LT).

233 is associated with mortality while awaiting liver transplantation (LT).

234 s develop chronic kidney disease (CKD) after liver transplantation (LT).

235 About 15% of liver transplantations (LTs) in Eurotransplant are curre

236 Currently, liver transplantation may be the optimal treatment for H

237 patients (89% female) with PBC who underwent liver transplantation (mean age, 54 +/- 9 years) from Fe

238 After orthotopic liver transplantation, metformin preconditioning signifi

239 Liver transplantation (n = 17) normalized B(T) and elimi

240 The major concern in liver transplantation of grafts from donation after circ

241 Successful liver transplantation offers the possibility of improved

242 n-making and organ allocation for orthotopic liver transplantation (OLT) and was previously upgraded

243 PV samples from IRI+ orthotopic liver transplantation (OLT) patients (n = 35) decreased

244 etabolic homeostasis, its role in orthotopic liver transplantation (OLT) remains elusive.

245 ith end-stage renal disease after orthotopic liver transplantation (OLT).

246 ary and cardiac failure following orthotopic liver transplantation (OLT).

247 t function in patients undergoing orthotopic liver transplantation (OLT).

248 The early liver transplantation option should therefore be explore

249 split livers or living donors as accelerated liver transplantation options.

250 Patients were enrolled while awaiting liver transplantation or 6-12 months posttransplant.

251 ntation and six patients (13%) had undergone liver transplantation or combined liver and kidney trans

252 itage was associated with increased risks of liver transplantation or PSC-related death compared with

253 remains a serious clinical problem affecting liver transplantation outcomes.

254 Conclusion: CRC screening in pre-liver transplantation patients is associated with a rela

255 48,261 adult liver transplantations, performed between 2000 and 2017

256 y-eight thousand two hundred sixty-one adult liver transplantations, performed between 2000 and 2017

257 Among patients with cirrhosis awaiting liver transplantation, prediction of wait-list (WL) mort

258 Liver transplantation provided an overall survival of 60

259 Liver transplantation provides the longest overall survi

260 ELS utilization and case-related liver transplantation rates were low (12.47%).

261 donor-specific HLA antibody (DSA) following liver transplantation remains controversial.

262 ocol liver biopsies (PB) following pediatric liver transplantation remains mostly uncharacterized, ye

263 rmacological approaches are ineffective, and liver transplantation represents the only curative optio

264 ere are increasing reports of combined heart-liver transplantation resulting from advanced liver dise

265 levels in plasma from patients who underwent liver transplantation revealed a significantly positive

266 didates for surgical resection, ablation and liver transplantation should be considered.

267 apy for patients with HCC who are listed for liver transplantation should be determined with consider

268 ients are good candidates for LR and salvage liver transplantation should be encouraged in eligible p

269 findings of disparities in accessibility of liver transplantation showed worse outcomes following li

270 Split liver transplantation (SLT) is 1 strategy for maximizing

271 summarizes the results of the International Liver Transplantation Society consensus meeting on NAFLD

272 h Joint Annual Congress of the International Liver Transplantation Society in association with Europe

273 Neoadjuvant chemoradiotherapy followed by liver transplantation substantially increases the surviv

274 age at the time of diagnosis with PBC or at liver transplantation, tacrolimus use, and biochemical m

275 t risk factor of liver graft steatosis after liver transplantation that is additive to the effects of

276 During the period after liver transplantation, the patient is recovering from su

277 Conclusion: Among patients who underwent liver transplantation, the presence of any exonic missen

278 In addition, we used a rat model of liver transplantation to compare survival of DCD grafts

279 We developed a program to offer liver transplantation to selected patients with HCC outs

280 orth American Working Group on Sarcopenia in Liver Transplantation to use evidence from the medical l

281 ty of 20 previously described biomarkers for liver transplantation tolerance in a cohort of 17 liver

282 he predictive strength of SENP6 and FEM1C in liver transplantation tolerance, there are also risks in

283 comes in 623 primary right lobe living donor liver transplantations, using grafts with (Group A; 10%-

284 out hepatocellular carcinoma who were on the liver transplantation waitlist at 9 centers in the Unite

285 irrhotic liver disease, as an indication for liver transplantation, was associated with lower risk of

286 x pancreas, liver, and rectal surgeries, and liver transplantation were analyzed over a 3-year period

287 the 17 patients who consented while awaiting liver transplantation were dosed.

288 Patients offered early liver transplantation were estimated to have an average

289 %) of 170 consecutive patients evaluated for liver transplantation were taking NSBB.

290 rative period in patients who have undergone liver transplantation, which will be used as a reference

291 teatotic grafts can be successfully used for liver transplantation with careful recipient selection.

292 he acceptance and improve the outcomes after liver transplantation with high-grade steatotic livers.

293 The risks of liver transplantation with steatotic donor livers could

294 m 81 patients who underwent HCC resection or liver transplantation, with curative intent, were used.

295 el graft protective strategy in the field of liver transplantation, with remarkable ongoing research

296 Evaluation of patients referred for liver transplantation within 30 days is associated with

297 x above 1.7 (HR 1.22; 95% CI 1.09-1.35), and liver transplantation within 30 days of listing (HR 0.89

298 Early liver transplantation (without requiring a minimum perio

299 Rapid induction of tolerance after liver transplantation would decrease these complications

300 recipients, offspring to parent living donor liver transplantation yields inferior long-term graft an